Literature DB >> 26843720

Tofacitinib.

.   

Abstract

Entities:  

Year:  2015        PMID： 26843720      PMCID： PMC4674023          DOI： 10.18773/austprescr.2015.080

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  6 in total

1.  Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.

Authors:  Joel Kremer; Zhan-Guo Li; Stephen Hall; Roy Fleischmann; Mark Genovese; Emilio Martin-Mola; John D Isaacs; David Gruben; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; Tamas Koncz; Richard Riese; John Bradley
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

2.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

Authors:  Roy Fleischmann; Joel Kremer; John Cush; Hendrik Schulze-Koops; Carol A Connell; John D Bradley; David Gruben; Gene V Wallenstein; Samuel H Zwillich; Keith S Kanik
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

3.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

4.  Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

Authors:  Gerd R Burmester; Ricardo Blanco; Christina Charles-Schoeman; Jürgen Wollenhaupt; Cristiano Zerbini; Birgitta Benda; David Gruben; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; Tamas Koncz; Koshika Soma; John Bradley; Charles Mebus
Journal:  Lancet       Date:  2013-01-05       Impact factor: 79.321

5.  Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.

Authors:  Désirée van der Heijde; Yoshiya Tanaka; Roy Fleischmann; Edward Keystone; Joel Kremer; Cristiano Zerbini; Mario H Cardiel; Stanley Cohen; Peter Nash; Yeong-Wook Song; Dana Tegzová; Bradley T Wyman; David Gruben; Birgitta Benda; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; John D Bradley; Carol A Connell
Journal:  Arthritis Rheum       Date:  2013-03

6.  Tofacitinib versus methotrexate in rheumatoid arthritis.

Authors:  Eun Bong Lee; Roy Fleischmann; Stephen Hall; Bethanie Wilkinson; John D Bradley; David Gruben; Tamas Koncz; Sriram Krishnaswami; Gene V Wallenstein; Chuanbo Zang; Samuel H Zwillich; Ronald F van Vollenhoven
Journal:  N Engl J Med       Date:  2014-06-19       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.